Compare IPGP & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPGP | ALKS |
|---|---|---|
| Founded | 1990 | 1987 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 4.5B |
| IPO Year | 2000 | 2012 |
| Metric | IPGP | ALKS |
|---|---|---|
| Price | $115.01 | $29.60 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 14 |
| Target Price | ★ $131.40 | $43.29 |
| AVG Volume (30 Days) | 423.8K | ★ 2.0M |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 117.85 | N/A |
| EPS | 0.73 | ★ 1.43 |
| Revenue | $1,003,777,000.00 | ★ $1,475,899,000.00 |
| Revenue This Year | $12.18 | $24.26 |
| Revenue Next Year | $8.44 | $4.63 |
| P/E Ratio | $162.44 | ★ $20.93 |
| Revenue Growth | ★ 2.73 | N/A |
| 52 Week Low | $48.59 | $25.17 |
| 52 Week High | $155.82 | $36.32 |
| Indicator | IPGP | ALKS |
|---|---|---|
| Relative Strength Index (RSI) | 46.34 | 51.21 |
| Support Level | $74.67 | $27.48 |
| Resistance Level | $141.43 | $30.36 |
| Average True Range (ATR) | 6.85 | 0.92 |
| MACD | -0.76 | 0.34 |
| Stochastic Oscillator | 35.15 | 80.21 |
IPG Photonics Corp is a vertically integrated developer and manufacturer of high-performance fiber lasers, laser and non-laser systems, fiber amplifiers, diode lasers, and related optical components. Its products are used in diverse applications in the manufacturing, automotive, industrial, aerospace, semiconductor, and consumer end markets. The company sells its products globally to original equipment manufacturers (OEMs), system integrators, and end users. Additionally, it manufactures complementary products used with its lasers, including optical delivery cables, fiber couplers, beam switches, optical processing heads, in-line sensors, and chillers. Geographically, the company generates maximum revenue from North America, followed by China, Japan, Germany, and other markets.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.